Published in
Taylor and Francis Group, Leukemia & Lymphoma, 3(58), p. 552-559
DOI: 10.1080/10428194.2016.1205741
Links
Tools
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study
Journal article published in 2016 by
Samantha Pozzi,
Massimo Gentile,
Stefano Sacchi,
Raffaella Marcheselli,
Alessandro Corso,
Federica Cocito,
Pellegrino Musto,
Attilio Guarini,
Carla Minoia 
,
Iolanda Vincelli,
Roberto Ria,
Elena Rivolti,
Giuseppe Mele,
Alessia Bari,
Carla Mazzone
and other authors.
,
Iolanda Vincelli,
Roberto Ria,
Elena Rivolti,
Giuseppe Mele,
Alessia Bari,
Carla Mazzone
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 